Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B440-2 triple combination therapy in unresectable malignant pleural mesothelioma
jRCT2051250111Phase 1Recruiting
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab, ipilimumab and B440 in pleural mesothelioma. Primary endpoints: Safety evaluation and Objective response rate. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on jRCT2051250111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250111.